Fresh from its clinical success with caplacizumab, Ablynx NV has priced its initial US public offering totaling $200m, propelling the company's market capitalization over the €1bn mark.
The Belgium-headquartered group has listed on the Nasdaq after selling 11.4 million American Depositary Shares (ADS) priced at $17.50 each....





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
